FDA Insists Its Quality Controls Are Up To The Task
Commissioner Scott Gottlieb and center for drug evaluation and research (CDER) director Janet Woodcock have insisted that the FDA is maintaining “strong oversight of generic drug quality issues domestically and abroad”.
You may also be interested in...
Draft guidance on quality considerations for continuous manufacturing has been published by the US Food and Drug Administration with a 90-day comment period.
Following the announcement in February that South Korea had been chosen by the WHO as the location for a global biomanufacturing training hub, a video shared by the IGBA has shed more light on what can be expected from the initiative.
Looking back over the third quarter of 2022, Generics Bulletin executive editor Dave Wallace picks out highlights from July to September that include changes in ownership on the horizon for major industry players, executive reshuffles at the top of leading companies and regulators, Generics Bulletin’s annual Top 50 and the announcement of our annual awards shortlist.